Description
Book SynopsisSGLT2 inhibitors, also called gliflozins, are a class of medications that inhibit reabsorption of glucose in the kidney and therefore lower blood sugar. They act by inhibiting sodium-glucose transport protein 2 (SGLT2). SGLT2 inhibitors are used in the treatment of type 2 diabetes mellitus.
This book is a concise guide to the use of SGLT2 inhibitors for the treatment of diabetes.
Beginning with an overview of the evolution and physiology of SGLT2 inhibitors, the following sections cover the renal, cardiovascular, and metabolic and haemodynamic effects of their use. Adverse effects are also examined.
The book concludes with detailed discussion on SGLT2 inhibitor use as a preferred option for management of type 2 diabetes, and currently emerging data for their successful use for treatment of type 1 diabetes.
Authored by recognised experts in the field, the book provides clinicians with the latest advances in the field, further enhanced by illustrations and figures to assist learning.
Key points
- Concise guide to use of SGLT2 inhibitors for management of diabetes
- Covers common use for treatment of type 2 diabetes as well as increasing use for type 1 diabetes
- In depth discussion on associated systemic effects
- Highly illustrated with diagrams and figures
Table of Contents
- The Evolution of SGLT-2 Inhibitors
- Physiology of SGLT-2 Inhibition: Role of Kidneys in Glucose Homeostasis in Type 2 Diabetes Mellitus
- Beyond Glycosuria: Exploring the Intrarenal Effects of SGLT-2 Inhibition in Diabetes
- Cardiovascular Outcome Trials with SGLT-2 Inhibitors
- Metabolic and Hemodynamic Effects of SGLT-2 Inhibitors
- Adverse Effects and Safety of SGLT-2 Inhibitors
- SGLT-2 Inhibitors in Diabetes: Place in Management Algorithms
- Clinical Pearls: Indications, Contraindications and Caution in Use of SGLT-2 Inhibitors
- SGLT-2 Inhibitors in Type 1 Diabetes: Emerging Evidences
- SGLT-2 Inhibitors and the Kidney: Lessons Learnt from CREDENCE Trial
